Catline Nobre
Villejuif, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Recurrent Resistance Mutations to Lirafugratinib Inform Treatment Sequencing in FGFR2-Driven Tumors.
Recurrent Resistance Mutations to Lirafugratinib Inform Treatment Sequencing in FGFR2-Driven Tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: November 15, 2025
NOX4-derived oxidative DNA damage impairs thyroid differentiation through an epigenetic mechanism in BRAF-mutated radioactive iodine refractory papillary thyroid cancer cells.
Journal: International journal of biological sciences
Published: August 18, 2025
Deciphering resistance mechanisms in cancer: final report of MATCH-R study with a focus on molecular drivers and PDX development.
Journal: Molecular cancer
Published: July 08, 2024
Understanding and Overcoming Resistance to Selective FGFR Inhibitors across FGFR2-Driven Malignancies.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: June 11, 2024
NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations.
Journal: Cancer discovery
Published: February 17, 2024
Development of Novel Models of Aggressive Variants of Castration-resistant Prostate Cancer.
Journal: European urology oncology
Published: July 21, 2023
Single-cell DNA-seq depicts clonal evolution of multiple driver alterations in osimertinib-resistant patients.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: July 23, 2021
Showing 1-8 of 8
Last Updated: 09/26/2026